News

Two distinct ways have bee identified that people with HIV can control the virus for an extended period after stopping antiretroviral therapy under medical supervision. This could inform efforts to develop new tools to help people with HIV put the virus into remission without taking lifelong medication, which can have long-term side-effects.

Researchers have created chemical compounds that can neutralize several variants of SARS-CoV-2 and stop infection of cultured human cells.

Researchers at MIT and Harvard University have designed a way to selectively turn on gene therapies in target cells, including human cells. Their technology can detect specific messenger RNA sequences in cells, and that detection then triggers production of a specific protein from a transgene, or artificial gene.

A new monoclonal antibody therapy called itepekimab shows promise as an alternative treatment for patients with moderate-to-severe asthma. Itepekimab was shown to be safe and effective in a Phase 2 trial, results were published in the journal New England Journal of Medicine.

Researchers have used a mathematical model to better understand the immune response to vaccines, which could help improve vaccine design and simplify the associated technical challenges.

A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has created a laser-powered device that can trap and move viruses using light.

A new method has been developed that uses artificial intelligence (AI) to foresee the most likely mutations of pathogens. The AI approach could help to design vaccines, drugs and diagnostic tests that are less likely to be impacted by emerging variants of concern.

At a time when the pace of vaccination in North Carolina was slowing, the $25 Summer Card Pilot program successfully encouraged more adults to get a COVID-19 vaccine.

With the U.S. approval of a third COVID-19 shot now expanded to Moderna and Johnson & Johnson recipients, the doors have opened for tens of millions of more Americans to boost their immunity against the coronavirus.

A dosing error made during an AstraZeneca-University of Oxford COVID-19 vaccine trial has led to a new dosage finding in mice.